ERCC1、RRM1、TS蛋白表达对晚期非小细胞肺癌个体化治疗的临床观察

来源期刊：广州医药 | 57-60 发布时间：2021-12-01 收稿时间：2025/11/13 17:09:35 阅读量：22

作者：: 赵美玲,

蔡小华,

杨方方,

向琪,

曹小飞,

关键词：: RRM1 ERCC1 TS 非小细胞肺癌

DOI：: 10.3969/j.issn.1000-8535.2017.05.015

收稿时间：: 2017-05-22
修订日期：
接收日期：
引用总数：: 0

目的探讨ERCC1、RRM1、TS蛋白表达对晚期非小细胞肺癌(NSCLC)个体化治疗的指导意义。方法收集经病理确诊的晚期NSCLC患者87例,其中67例愿意接受药敏免疫组化检测的患者作为研究组,采用SP法检测肿瘤组织ERCC1、RRM1、TS蛋白表达,并根据蛋白表达情况选择化疗方案;另外20例患者不进行药敏免疫组化检测,以常规吉西他滨联合顺铂方案化疗,以此作为对照组。比较两组患者化疗的有效率,疾病控制率(DCR),并以无进展生存期(PFS)为指标比较患者预后。结果研究组67例患者中,PR 33例(49.25%),SD 13例(19.4%),PD 21例(31.35%);对照组20例患者中,PR 4例(20%),SD 4例(20%),PD 12例(60%),两组疗效之间有差异( χ²=6.437,P=0.04),研究组DCR为68.6%,高于对照组DCR 40%,差异有统计学意义(χ²=5.372,P=0.034)。研究组患者的中位PFS高于对照组,研究组的PFS为5月,对照组为3月,差异有统计学意义(P＜0.05)。结论对晚期NSCLC患者进行ERCC1、RRM1、TS药敏蛋白免疫组化检测,指导个体化治疗方案,能提高患者化疗的疾病控制率及延长患者的疾病进展时间。

1、 WANG X, WANG Y, WANG Y, et al. Association of thymidylate synthase gene 3′-untranslated region polymorphism with sensitivity of non-small celllung cancer to pemetrexed treatment:TS gene polymorphism and pemetrexed sensitivity in NSCLC[J]. J Biomed Sci,2013(20):5.

2、 KIM S O, JEONG J Y, KIM M R,et al: Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene[J]. Clin Cancer Res, 2008, 14(10):3083-3088.

3、 COBO M, ISLA D, MASSUTI B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing1 mRNA expression: a phase Ⅲ trial in non-small-cell lung caner[J]. J Clin Oncol, 2007, 25(19): 2747-2754.

4、 ALTAHA R, LIANG X, YU J J, et al. Excision repair cross complementinggroup1: gene expression and platinum resistance[J]. Int J Mol Med,2004,14(6):959-970.

5、崔同建,刘振华,陈峥,等.晚期非小细胞肺癌4种化疗方案临床对照研究[J]. 肿瘤学杂志,2006,12(2):136-138.

6、李红梅,李海霞,刘克为,等.含顺铂三种化疗方案治疗非小细胞肺癌的临床研究[J]. 山东大学学报(医学版),2007,45(5):499-502.

7、 KASSIS E S, VAPORCIYAN A A, SWISHER S G, et al. Application of the revised lung cancer staging system (IASLC staging project) to a cancer center population[J]. J Thorac Cardiovasc Surg, 2009, 138(2):412-418.

8、 RIGHI L, PAPOTTI M G, CEPPI P, et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy[J]. J Clin Oncol, 2010, 28(9): 1534-1539.

9、 LEE J J, MAENG C H, BAEK S K,et al. The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC)[J]. Lung Cancer, 2010, 70(2):205-210.

10、 OLAUSSEN K A, DUNANT A, FOURET P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy[J]. N Engl J Med, 2006, 355(10):983-991.

11、 ZUCALI P A, GIOVANNETTI E, DESTRO A, et al. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin[J]. Clin Cancer Res,2011,17(8):2581-2590.

12、 BOUKOVINAS I, PAPADAKI C, MENDEZ P, et al. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients[J]. PLoS One, 2008, 3(11):e3695.

13、 LENG X F, CHEN M W, XIAN L, et al. Combined analysis of mRNA expression of ERCC1,BAG-1,BRCA1,RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy[J]. J Exp Clin Cancer Res,2012, 31 (1):25.

14、 OHE Y, OHASHI Y, KUBOTA K,et al. Randomized phase Ⅲ study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-arm cooperative study in Japan[J]. Ann Oncol, 2007, 18(2):317-323.

15、 SCHILLER J H, HARRINGTON D, BELANI C P,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med, 2002, 346(2): 92-98.